Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-Like Particle Vaccine ( Norwalk VLP Antigen, MPL, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device).

Trial Profile

Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-Like Particle Vaccine ( Norwalk VLP Antigen, MPL, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device).

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2015

At a glance

  • Drugs Norovirus vaccine (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions
  • Sponsors LigoCyte Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2010 Results will be presented at the 13th Annual Conference on Vaccine Research, according to a LigoCyte Pharmaceuticals' media release.
    • 09 Dec 2009 Planned end date (1 Oct 2009) added as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top